Loading…
Loading…
Walk us through what's given you confidence here in moving forward with a Phase three study in CIDP and the opportunity in that indication?
you also noted that the event rate for the OCEAN(a) outcome study is lower than you expected. Could you just speak to your confidence in this program
curious here as to your thoughts on that clause specifically, but additionally, how you are thinking about DTC efforts, which seem to be a growing theme across the industry
could you just help us understand the commercial strategy, including the relevant prescribers and patient identification efforts for the former?
can you speak to where you feel The Street is underappreciating growth and discuss how you factored in the Part D redesign to your projections?
Could you just comment on the inventory impact for Yeztugo in the third quarter and also how the CVS pricing discussions are progressing
can you just share any details on how much of the US market is supplied by ex-US manufacturing, either API finished product